PVCT.US Provectus Biopharmaceuticals Inc

Healthcare Pharmaceuticals USA Stocks
0.0426 USD
Close of Nov 17, 2026
0.0380 0.0770
Market cap
USD 17.9M
P/E
-
P/B
5.44x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is PVCT.US undervalued?

Graham number

The Graham number of Provectus Biopharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Provectus Biopharmaceuticals Inc fundamental analysis

No fundamental analysis for Provectus Biopharmaceuticals Inc yet.

Provectus Biopharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Provectus Biopharmaceuticals Inc

Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines for various diseases in the United States. The company's lead molecule is rose bengal sodium, a class of bioactive synthetic small molecules halogenated xanthenes. Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers and breast cancers; PH-10 for the treatment of psoriasis and …

Full company profile